Estimating Changes in Medicare Part D and Commercial Insurer Insulin Spending Amid Planned State-Led Biosimilar Insulin Production in California

This cross-sectional study evaluates the cost savings of state-led manufacturing and selling of biosimilar insulin.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of internal medicine (1960) 2023-07, Vol.183 (7), p.734-735
Hauptverfasser:	Anderson, Kelly E, Xuan, Andrew, Anderson, Gerard F, Socal, Mariana P
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Biological products Biosimilar Pharmaceuticals California Health care expenditures Health Expenditures Health insurance Humans Insulin Insulin - therapeutic use Insurance Carriers Letters Medicare Medicare Part D Online First Pharmaceutical industry Research Letter United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This cross-sectional study evaluates the cost savings of state-led manufacturing and selling of biosimilar insulin.
ISSN:	2168-6106 2168-6114
DOI:	10.1001/jamainternmed.2023.0373